Archived AES Symposia 2005
Merritt-Putnam Symposium - Pharmacoresistance: From Clinic to Mechanism
Program Length: 2 hrs 39 min
Why do antiepileptic drugs fail? What do we still need to understand about the mechanisms of epilepsy, the actions of drugs, and the effects of prolonged drug treatment to improve the pharmacotherapy of epilepsy? This symposium will explore the topic of pharmacoresistance. First, we will consider the complexity of the clinical problem. Then we will examine changes in two brain mechanisms that confer resistance to AEDs: transport and targets. Membrane transporters alter levels of drugs in epileptic foci. What effects do seizures, AEDs, seizure control, and genetic defects have on transporter expression and function? Ion channels are the targets of many AEDs. Does molecular plasticity of AED targets due to epilepsy or prolonged drug exposure contribute to pharmacoresistance? The symposium will also describe monitoring gene changes in persons with epilepsy during AED therapy. Finally, the program will close with a discussion on how clinicians and scientists can work together in designing clinical trials for the next generation of AEDs that can address specific questions regarding the development of pharmacoresistance.
At the conclusion of this activity, participants should be able to:
- Recognize the clinical spectrum of response to current antiepileptic drug therapy
- Explain how AEDs enter the brain and the molecules that regulate their concentration
- Describe mechanisms that alter neuronal ion channel responses to antiepileptic drugs
- Discuss the future use of genomics to monitor biological effects of chronic AED therapy
- Evaluate the research design of clinical studies to determine optimal drug efficacy.
Epileptologists, neurologists, neuroscientists, pharmacists, residents, and other healthcare professionals involved in the care of persons with epilepsy.
Chair: Jeffrey L. Noebels, M.D., Ph.D.
This program and its repurposing on the AES Web site with CME credit is supported by an educational grant from Pfizer Inc.
Disclosure: It is the policy of the American Epilepsy Society that all faculty participating in continuing medical education activities are expected to disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. The American Epilepsy Society adheres to the ACCMEs Essential Areas and Policies regarding industry support of continuing medical education. Disclosure by faculty of commercial relationships, if any, and discussions of unlabeled or unapproved uses will be made.
Jeffrey L. Noebels, MD, PhD has disclosed that he has no significant relationships with commercial supporters. Dr Noebels has disclosed that he does not intend to discuss the unlabeled/unapproved use of any products.
Heinz Beck, MD has disclosed that he has no significant relationships with commercial supporters. Dr Beck has disclosed that he does not intend to discuss the unlabeled/unapproved use of any products.
Marc A. Dichter, MD, PhD has disclosed that he has received consulting fees from UCB Pharma, Inc. Dr Dichter has disclosed that he does not intend to discuss the unlabeled/unapproved use of any products.
Jacqueline A. French, MD has disclosed that she has received consulting fees from Pfizer, Inc., UCB Pharma, Inc., GlaxoSmithKline, Ortho-McNeil Pharmaceutical, Inc., Eisai Inc., and Novartis Pharmaceutical Corporation. She has also received fees for non-CME services from UCB Pharma and Eisai. In addition, Dr French has received research funds from Pfizer,UCB Pharma, Eisai, and Ortho-McNeil. Dr French has disclosed that she does not intend to discuss the unlabeled/unapproved use of any products.
Tracy A. Glauser, MD has disclosed that he has received consulting fees from Ortho-McNeil Pharmaceutical, Inc., Johnson & Johnson Pharmaceutical Research & Development, Novartis Pharmaceutical Corporation, UCB Pharma, Inc., and Eisai Pharmaceutical Co. He has received fees for non-CME services from Ortho-McNeil, Novartis,UCB Pharma, and Eisai. In addition, Dr Glauser has received research grants from UCB Pharma. Dr Glauser has disclosed that he does not intend to discuss the unlabeled/unapproved use of any products.
Wolfgang Lscher, PhD has disclosed that he has received consulting fees and grants/research support from Desitin Arzneimittel GmbH (Germany) and UCB Pharma, Inc (Belgium). Dr Lscher has disclosed that he does not intend to discuss the unlabeled/unapproved use of any products.
Disclaimer: Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any manufacturers of pharmaceuticals.